QDEL - Quidel more quick diagnosis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis

QDEL 21.31

+1.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Randy Atkins who wrote (807)	5/16/1997 8:23:00 AM
From: Howard Schellenberg	of 1693

Notes from Conference Call: 1. P&G Marketing costs will decrease in out quarters. 2. h Pylori sales from P&G will not show until out quarters. 3. Operating costs growth will be 2/3 of sales growth in future. Therefore, earnings will continue to outpace expenses. 4. No pricing pressures domestically, except in pregnancy testing. 5. BDX lawsuit is groundless, according to the company. Company will not comment further on the lawsuit. 6. Strong dollar cost company $145,000 in the quarter. 7. Glaxo will continue to support company efforts in influenza. 8. Significant improvement in inventory turnover (or turns) this FY. Also, note that CellPro, the loser in a very similar lawsuit with BDX, is now trading above $8.00 a share. They were about at $5.00 when the lawsuit was settled. Just goes to show you how these are one-time events.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next